New hospital purchasing guidelines in Germany could force medtech companies to rethink traditional strategies
This article was originally published in Clinica
The German market for medical devices is by no means as open to innovation as it was a few years ago. The criteria for paying for treatment by health insurers have been expanded to include cost-efficiency although the evaluation formulae have not yet been established. But, say consultants Hans-Jurgen Wildau and Bernd Grohs, potentially expensive outlays for developing innovative medical products can be reduced by integrating partners from different healthcare sectors early on.
You may also be interested in...
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.
Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment.